Meta-Analysis Comparing P2Y12 Inhibitors in Acute Coronary Syndrome

This publication has 24 references indexed in Scilit:

• Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30day mortality in patients with ST-elevated myocardial infarction
  International Journal of Cardiology, 2015
• Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland
  Heart, 2015
• Outcomes in Patients With ST-Segment Elevation Acute Myocardial Infarction Treated With Clopidogrel Versus Prasugrel (from the INFUSE-AMI Trial)
  The American Journal of Cardiology, 2014
• Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
  New England Journal of Medicine, 2009
• The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention
  JACC, 2009
• Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
  The Lancet, 2009
• A Perspective on the Efficacy and Safety of Intensive Antiplatelet Therapy in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
  The American Journal of Cardiology, 2008
• Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
  New England Journal of Medicine, 2007
• Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome
  JACC, 2007
• Combination of direct and indirect evidence in mixed treatment comparisons
  Statistics in Medicine, 2004